Research
Hormonal
Acute administration of glucose (oral or intravenous) and food intake causes a significant decrease in plasma ghrelin concentrations, reaching a nadir of approximately 66-69% of basal levels, indicating ghrelin reflects acute feeding state.
Eating food, particularly carbohydrates, triggers a rapid drop in ghrelin (the hunger hormone). This is a metabolic signal, not just a result of your stomach being physically full. Water alone does not trigger this hormonal drop, suggesting that nutrient content is key to hormonal satiety.
GoodSupportsHIGH confidence
Plasma ghrelin concentrations of normal subjects decreased significantly after oral and iv glucose administration... reaching a nadir of 69% of the basal level after the meal.
Source
Plasma Ghrelin Levels in Lean and Obese Humans and the Effect of Glucose on Ghrelin Secretion
Tomomi Shiiya et al. · The Journal of Clinical Endocrinology & Metabolism · 2002
DOI 10.1210/jcem.87.1.8129
cross_sectional · n=98Cited 1,265×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Fasting plasma ghrelin concentrations are negatively correlated with body mass index (BMI), with lower levels in obesity and higher levels in anorexia nervosa, indicating that chronic positive energy balance suppresses ghrelin secretion.Good
- Plasma ghrelin exhibits a diurnal pattern with preprandial increases and postprandial decreases, peaking at 0200 h, suggesting ghrelin acts as a meal-initiation signal entrained to sleep and meal timing.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →